First Once-Weekly Oral HIV Treatment Demonstrates Safety and Efficacy

Дата публикации: 07-08-2026 00:00:00

Patients with HIV who took once-weekly islatravir and lenacapavir tablets maintained virological suppression in investigational trials, the drug manufacturers announced.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy	0	12.6	21-07-2026
2	ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia	0	12.15	06-10-2026
3	<![CDATA[Long-Acting Cabotegravir/Rilpivirine Superior to Daily Oral ART for HIV ]]>	0	13.67	06-10-2026
4	ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026	0	18.78	21-07-2026
5	Malawi: United States Delivers Breakthrough HIV Prevention Medication to Malawi	5	7	07-07-2026
6	В Минздраве заявили о достаточном запасе препаратов для лечения ВИЧ в России	0	0	17-04-2020
7	SNAP Benefit Cycles and Antiretroviral Therapy Adherence Among Adults With HIV	0	5.53	05-08-2026
8	The drug lenacapavir is a mighty weapon against HIV. Its rollout gets mixed reviews	0	7.66	13-08-2026
9	Lenacapavir: inovação para quem?	0	9.91	28-07-2026
10	International study helps support FDA approval of HIV drug for newborns	0	6.2	22-10-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.22. Источник: jamanetwork.com.